Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)

PURPOSE: This study investigated the efficacy and safety of cetuximab-based treatment in patients with chemotherapy-resistant refractory mCRC with KRAS G13D mutation. PATIENTS AND METHODS: An assessment of the efficacy and safety of cetuximab-based treatment was performed in an observation-enriched...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Chemother Pharmacol
Hauptverfasser: Nakamura, Masato, Aoyama, Toru, Ishibashi, Keiichiro, Tsuji, Akihito, Takinishi, Yasutaka, Shindo, Yoshiaki, Sakamoto, Junichi, Oba, Koji, Mishima, Hideyuki
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer Berlin Heidelberg 2016
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5225170/
https://ncbi.nlm.nih.gov/pubmed/27878354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3203-7
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge